Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jan;39(1):315-324.
doi: 10.1007/s00467-023-06102-w. Epub 2023 Jul 25.

Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement

Dermot Michael Wildes  1 , Susan Harvey  2   3 , Caoimhe Suzanne Costigan  4 , Clodagh Sweeney  4 , Éilis Twomey  5 , Atif Awan #  4   3   6 , Kathleen Mary Gorman #  2   3
Affiliations
Case Reports

Eculizumab in STEC-HUS: a paradigm shift in the management of pediatric patients with neurological involvement

Dermot Michael Wildes et al. Pediatr Nephrol. 2024 Jan.

Abstract

Background: Eculizumab for the treatment of atypical hemolytic uremic syndrome (HUS) is a standard of care. Central nervous system (CNS) involvement in Shiga toxin-producing Escherichia coli (STEC)-HUS is associated with increased morbidity and mortality. There is no consensus on the use of plasma exchange and/or eculizumab. We report a series (n = 4) of children with CNS involvement in STEC-HUS with excellent outcomes after treatment with eculizumab only and supportive therapies.

Methods: A retrospective chart review of patients with CNS involvement in STEC-HUS is managed with supportive therapies and eculizumab only.

Results: Four patients (75% female) with a median age of 5 years and 11 months (IQR: 23.5-105.5 months) were admitted to a tertiary pediatric nephrology center with CNS involvement in STEC-HUS. Neurological symptoms presented between days 2 and 7 of illness and included ataxia, altered mental status, visual symptoms, and seizures. All had an abnormal MRI brain. All received two doses of eculizumab, 1 week apart (dosing according to weight). Resolution of neurological symptoms was evident at a mean of 60 h post-administration (range: 24-72 h). All patients have complete kidney and neurological recovery at 12-month follow-up.

Conclusion: We present a case series of four children with STEC-HUS and CNS involvement, managed with eculizumab only, in lieu of plasma exchange (as per our previous policy). The marked improvement in symptoms in our cohort supports the use of eculizumab, rather than plasma exchange in the CNS involvement of STEC-HUS.

Keywords: CNS involvement; Eculizumab; STEC-HUS.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Noris M, Remuzzi G (2005) Hemolytic uremic syndrome. J Am Soc Nephrol 16:1035–1050 - DOI - PubMed
    1. Lynn RM, O’Brien SJ, Taylor CM et al (2005) Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerg Infect Dis 11:590–596 - DOI - PubMed - PMC
    1. Costigan C, Raftery T, Carroll AG et al (2022) Neurological involvement in children with hemolytic uremic syndrome. Eur J Pediatr 181:501–512 - DOI - PubMed
    1. Khalid M, Andreoli S (2019) Extrarenal manifestations of the hemolytic uremic syndrome associated with Shiga toxin-producing Escherichia coli (STEC HUS). Pediatr Nephrol 34:2495–2507 - DOI - PubMed
    1. Brown CC, Garcia X, Bhakta RT, Sanders E, Prodhan P (2021) Severe acute neurologic involvement in children with hemolytic-uremic syndrome. Pediatrics 147:e2020013631 - DOI - PubMed

Publication types

LinkOut - more resources